NOVEL FOOD AUTHORIZATIONS: PHENYLCAPSAICIN AND ‘2'-FUCOSYLLACTOSE/DIFUCOSYLLACTOSE MIXTURE
Jan 01, 2020
The implementing regulations for the authorization of the novel foods phenylcapsaicin and â2'-fucosyllactose/difucosyllactose mixture have been published in the EU official journal. Both substances will be authorized for use in food supplements.
â2'-Fucosyllactose/Difucosyllactose mixture is authorized for use in food supplements with an intake of maximum 4 g per day. Phenylcapsaicin is authorized for use in food supplements destined for adults and cchildren older than 11 years with a maximum daily intake of 2,5 mg per day.
Commission implementing Regulation (EU) 2019/1979 of 26 November 2019 authorising the placing on the market of 2'-Fucosyllactose/Difucosyllactose mixture as a novel food - link
Commission Implementing Regulation (EU) 2019/1976 of 25 November 2019 authorising the placing on the market of Phenylcapsaicin as a novel food - link
Conditions of use of the novel food galacto-oligosaccharide
European Union
Aug 10, 2022
Conditions of use of the novel food Schizochytrium sp. oil rich in DHA and EPA
European Union
Aug 10, 2022
Iron hydroxide adipate tartrate authorized as a novel food
European Union
Aug 10, 2022
The Regulation of Dietary Supplements in the United States
USA
Aug 04, 2022
Amendments to food regulations
Vietnam
Aug 04, 2022
Policy regarding N-acetyl-L-cysteine
USA
Aug 03, 2022
14 novel food ingredients of plant origin
Turkey
Jul 26, 2022
Addition of phytosterols, phytostanols or their esters as a novel food to plant-based milk alternatives
Australia
Jul 25, 2022
Regulation on supplementary food
Turkey
Jul 25, 2022
Amendments to the Food and Drug Regulations on supplemented foods
Canada
Jul 20, 2022
Revisiting Novel Food Regulation
European Union
Jul 18, 2022
Regulatory Responses to the Use of Nanoscale Substances in Food in ASEAN
Jul 18, 2022
Edible insect consultation
UK
Jul 18, 2022
Amendments to Regulation on natural health products
Canada
Jul 18, 2022
USA - Lack of supplement regulation: A potential for ethical and physiological repercussions
USA
Jul 11, 2022
